Increasing the transcriptional activity of CEBPα using short-activating RNA (saRNA) promoted the reversal of HCC development in a rat model, and it is currently being tested in a phase I study as a novel therapeutic oligonucleotide [32]. Here, CEBPA is linked to hepatocellular carcinoma.